Search Results
Oct 30, 2025, 10:06 ET Bestselling Author B.J. Steele Launches 9th Novel -- The Secrets We Keep -- Introducing the Passion-Fueled New "Secret Series"
Media Contact: B.J. Steele Books B. J. [email protected]
More news about: B.J. Steele
Oct 30, 2025, 09:08 ET Ben Rubinowitz Ranked #1 and Howard S. Hershenhorn Among Top 10 on 2025 New York Metro Super Lawyers List; 12 Attorneys from Gair, Gair, Conason, Rubinowitz, Bloom, Hershenhorn, Steigman & Mackauf Honored
Ben B. Rubinowitz, Howard S. Hershenhorn, Jeffrey B. Bloom, Richard M. Steigman, Diana M.A. Carnemolla, Peter J. Saghir, Marijo C. Adimey, and Christopher J. Donadio, were named Super Lawyers, while Richard Soldano, Aaron M. Ser, Jacob Green, and Joseph Lund Lasher were recognized as
More news about: Gair, Gair, Conason, Rubinowitz, Bloom, Hershenhorn, Steigman & Mackauf
Oct 30, 2025, 09:00 ET Harness Collaborates with Google Cloud to Bring AI to Software Delivery
"Enterprises want the speed and creativity AI can bring, but they also need the security, governance, and scale to trust it in production," added Ryan J. Salva, Senior Director of Product Management, Google Cloud. "Harness AI shows exactly how Vertex AI can deliver on those needs, helping global development
More news about: Harness
Oct 30, 2025, 08:48 ET Gorayeb & Associates Issues Safety Alert Following Rising Electrocution Deaths on New York Construction Sites
construction sites, yet we continue to see workers die or suffer catastrophic injuries because basic safety measures aren't being followed," said Christopher J. Gorayeb, Founder and Managing Partner of
More news about: Gorayeb & Associates
Oct 30, 2025, 08:42 ET NetCarrier Appoints Aaron Laam as Senior Director, Voice Solutions -- Advancing AI-Driven Innovation in Unified Communications
trust and transparency. "Aaron brings an exceptional blend of technical expertise and customer-focused leadership," said Brook J. Lenfest, President & CEO of NetCarrier. "His ability to translate innovation into real-world impact will be instrumental as we continue embedding
More news about: NetCarrier
Oct 30, 2025, 08:33 ET STEMup Science and Technology Institute™ and Connexis Search Group Launch National Partnership to Advance Fractional Leadership and Workforce Innovation in STEM and Life Sciences
"Our collaboration with Connexis bridges the gap between education, employment, and enterprise creation," said Dr. Neil J. Campbell, Executive Chairman of STEMup Science and Technology Institute. "By embedding fractional leadership and executive development into our
More news about: STEMup Science & Technology Institute
Oct 30, 2025, 08:00 ET GT Medical Technologies Welcomes New GammaTile® Center of Excellence Program Designation
operable brain tumors," said Dr. Ganesh Rao, Physician Lead for the Neuroscience Service Line at Baylor St. Luke's Medical Center and Professor and Marc J. Shapiro Chair of Neurosurgery at Baylor College of Medicine. "With GammaTile, we can deliver targeted radiation precisely where it is needed at the time
More news about: GT Medical Technologies
Oct 30, 2025, 08:00 ET Mallinckrodt to Present Data on Terlipressin in Patients with Hepatorenal Syndrome-Acute Kidney Injury (HRS-AKI) at Kidney Week 2025
https://www.census.gov/quickfacts/fact/table/US/PST045218. Accessed October 2025.7 Wong R.J., Balasubramanain J., Panaccio M., et al. Acute Kidney Injury and Hepatorenal Syndrome Among Hospitalized Patients With Chronic Liver Disease. JAMA Netw Open. 2025;8(5):e2511816.
More news about: Mallinckrodt plc
Oct 30, 2025, 07:35 ET Knight Therapeutics anuncia a aprovação e o lançamento do MINJUVI® (tafasitamabe) na Argentina
difuso de grandes células B refratário primário e com recidiva precoce. Am Soc Clin Oncol Educ Book. 2023 Jan;43:e390802 Duell, J et al. Resultados a longo prazo do estudo L-MIND de Fase II com tafasitamab (MOR208) mais lenalidomida em pacientes com linfoma difuso de grandes células
More news about: Knight Therapeutics Inc.
Oct 30, 2025, 07:35 ET Knight Therapeutics anuncia la aprobación y el lanzamiento de MINJUVI® (tafasitamab) en Argentina
Primary Refractory and Early Relapsed Diffuse Large B-Cell Lymphoma. Am Soc Clin Oncol Educ Book. 2023 Jan;43:e390802 Duell, J et al. Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large
More news about: Knight Therapeutics Inc.
Oct 30, 2025, 07:05 ET Revolutionizing Operations: How Customers Are Benefiting from Cyngn's DriveMod Tugger
G&J Pepsi, this has been an important year for the company.
More news about: Cyngn
Oct 30, 2025, 07:00 ET CytoSorbents to Report Third Quarter 2025 Financial Results and Recent Business Highlights
otherwise, other than as required under the Federal securities laws. U.S. Company Contact: Peter J. Mariani, Chief Financial Officer305 College Road EastPrinceton, NJ 08540
More news about: Cytosorbents Corp
Oct 30, 2025, 07:00 ET International Paper Reports Third Quarter 2025 Results
The Company's cost for third-party damages associated with a warehouse fire in Morocco. See note (j) of the Consolidated Statement of Operations.
More news about: International Paper
Oct 30, 2025, 07:00 ET BNCCORP, INC. REPORTS THIRD QUARTER NET INCOME OF $2.6 MILLION, OR $0.74 PER DILUTED SHARE
"Our third quarter performance reflects disciplined execution and continued progress in improving profitability," said Daniel J. Collins, BNC's President and Chief Executive Officer. "We delivered meaningful improvements in both return on assets and on equity. Net income increased
More news about: BNCCORP, INC.
Oct 30, 2025, 07:00 ET Howmet Aerospace Reports Third Quarter 2025 Results
meet increased demand, production targets or commitments; (i) competition from new product offerings, disruptive technologies or other developments; (j) geopolitical, economic, and regulatory risks relating to Howmet Aerospace's global operations, including geopolitical and diplomatic tensions, instabilities,
More news about: Howmet Aerospace Inc.
Oct 30, 2025, 06:58 ET Rebellion's Heartland 3 Project Earns 'AA' MSCI Carbon Project Rating, Validating Premium-Quality Methane-Abatement Credits
investment promotion, expert opinion, assurance, offering document, or recommendation to buy or sell securities, credit commitments, or other assets; (j) is based partly on information provided by the rated project, which the MSCI Parties do not verify; (k) may include non-public information and differ
More news about: Rebellion Energy Solutions
Oct 30, 2025, 06:45 ET Columbus McKinnon Reports 8% Sales Growth in Q2 FY26 and Reaffirms Guidance
"Our team delivered a solid second quarter as the U.S. short-cycle market recovered and we executed on our record backlog," said David J. Wilson, President and Chief Executive Officer. "Our funnel of quotation activity remains healthy, driven by attractive global opportunities and an improving
More news about: Columbus McKinnon Corporation
Oct 30, 2025, 06:05 ET Escalade Reports Third Quarter 2025 Results
delivered strong third-quarter results, driven by sustained demand for our leading brands and our ongoing commitment to operational excellence," said Patrick J. Griffin, Escalade's Interim President and Chief Executive Officer. "Our results are especially encouraging given the challenging macro environment, where
More news about: Escalade, Incorporated
Oct 30, 2025, 06:00 ET Escalade Announces Executive Management Change
30, 2025 /PRNewswire/ -- Escalade, Inc. (NASDAQ: ESCA, or the "Company") announced today that the Escalade Board of Directors appointed Patrick J. Griffin as Escalade's Interim President and Chief Executive Officer effective immediately. Mr. Griffin replaced Armin Boehm, who has resigned from the
More news about: Escalade, Incorporated
Oct 29, 2025, 22:42 ET 雲頂新耀與Visara簽訂協議 將在大中華區及其他亞洲市場開發及商業化VIS-101
新橋生物首席執行官傅希湧博士表示：「此次將VIS-101大中華區、韓國及東南亞地區的權益授權給雲頂新耀，是我們在優化全球商業佈局、推動全球臨床開發協同方面邁出的重要一步。我們期待與雲頂新耀共同推進該產品在亞洲地區的戰略協作，為更多患者帶來創新治療選擇。」 Visara聯合創始人兼執行董事長Emmett J. Cunningham, Jr.博士表示：「 VIS-101有望成為該類別第二款上市的藥物，並具備同類最佳的潛力，這源於其在生物工程上的優異設計，使其具備更強的靶點中和能力。我們非常高興攜手雲頂新耀推進VIS-101，加速將這款針對AMD、DME和RVO的創新療法帶給更多中國及亞洲地區的患者。」
More news about: 雲頂新耀
Oct 29, 2025, 21:33 ET WITH 3 OUT OF 4 CAR SEATS IMPROPERLY INSTALLED, NEW VIRTUAL SERVICE HELPS ENSURE PROPER CAR SEAT INSTALLATION
https://prnewswire2-a.akamaihd.net/p/1893751/sp/189375100/serveFlavor/entryId/1_ybev8ws3/flavorId/1_4j7xy9mh/prn_folder/MNR/prn_id/MVP/prn_flavor/Source/prn_filename/9361851_Virtual_carseat_package_no_voice_over.mp4 Vídeo -
More news about: Buckle Up for Life
Oct 29, 2025, 21:07 ET Delonix Group Kian Gencar Berekspansi di Indonesia dengan Membuka Model J Hotel Jakarta Central Park
wisatawan maupun investor. Model J Central Park: Pengalaman Menginap dengan Layanan Unggulan di Pusat Kota Jakarta Model J Hotel Jakarta Central Park menghadirkan 107 kamar hotel yang dirancang
More news about: Delonix Group
Oct 29, 2025, 20:22 ET PORQUE 3 DE CADA 4 SILLAS DE SEGURIDAD SON INSTALADAS INCORRECTAMENTE, HAY UN NUEVO SERVICIO VIRTUAL QUE AYUDA A GARANTIZAR UNA INSTALACIÓN ADECUADA DE LA SILLAS DE SEGURIDAD PARA NIÑOS
https://prnewswire2-a.akamaihd.net/p/1893751/sp/189375100/serveFlavor/entryId/1_ybev8ws3/flavorId/1_4j7xy9mh/prn_folder/MNR/prn_id/MVP/prn_flavor/Source/prn_filename/9361851_Virtual_carseat_package_no_voice_over.mp4 Vídeo -
More news about: Buckle Up for Life
Oct 29, 2025, 20:10 ET 歌禮選定同類最佳每月一次皮下注射胰澱素受體激動劑ASC36進入臨床開發階段
歌禮將於中國標准時間2025年10月30日上午10:00舉行電話交流會（普通話）。可通過Zoom會議號：978 3932 9387，或如下的鏈接參與直播： https://zoom.us/j/97839329387。 關 於歌 禮 制
More news about: 歌禮製藥有限公司
Oct 29, 2025, 20:10 ET Ascletis Selects a Best-in-Class Once-Monthly Subcutaneously Administered Amylin Receptor Agonist, ASC36, for Clinical Development
via Zoom, with the Meeting ID: 978 3932 9387, or access link of: https://zoom.us/j/97839329387. About Ascletis Pharma Inc. Ascletis
More news about: Ascletis Pharma Inc.